Almost three in four (73%) oncology research executives plan to execute either a fully decentralized or hybrid clinical trial in the next 12 months.
Science 37 published new data from oncology clinical research executives, indicating three-quarters of all planned new oncology study starts over the next 12 months will include elements of decentralization.
Among the findings:
- The biggest perceived challenges with traditional oncology clinical trials (including both traditional studies and agile/DCTs) are Patient Recruitment (72% of execs ranked it in their top three), Study Start-Up (55%), and Timeline/Delays (54%).
- The top three perceived benefits of using agile/DCT tools in oncology trials are Increased Patient Retention (which 67% of respondents ranked in their top three), Greater Patient Diversity (54%), and Faster Patient Recruitment (50%).
Read more about the data here.
